DocMorris AG informa de un sólido rendimiento en el primer semestre de 2024, con la mirada puesta en el crecimiento de eRx.
We are confident in the future of eRx in Germany and our digital health strategy, focusing on customer acquisition and retention. TeleClinic has also seen significant growth, doubling its sales in the first half of 2024 and reaching breakeven in the last quarter of 2023. We are on track for profitable growth and anticipate a … Leer más